Doppl supplies industry‑standard organoid models for disease modeling and personalized medicine, offering custom model development, toxicity screening, and epithelial fluid transport assays. Their portfolio supports preclinical drug development across oncology, inflammatory, rare, and immuno‑oncology applications. The company also provides a crowd‑sourced bio‑base of donor samples to enable scalable, high‑quality organoid research.
Funding
$100K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional preclinical drug testing often relies on animal models or cell lines that do not accurately represent human biology, leading to ineffective or toxic compounds advancing to clinical trials. The lack of relevant and scalable disease models hinders the development of personalized medicine approaches.
Solution
Doppl provides industry-standard organoid models derived from human biological samples to improve the accuracy and scalability of preclinical drug development. The company's crowd-sourced biobank enables the creation of organoids that closely mimic human tissues and diseases, offering a more relevant platform for compound profiling, target validation, and mechanistic studies. Doppl develops customized organoid lines that accurately model specific tissues or diseases of interest, including oncology, inflammatory diseases, and rare diseases. These organoid models can be used for toxicity screening, epithelial fluid transport analysis, and immuno-oncology research. By using human-derived organoids, Doppl aims to accelerate the development of effective and personalized therapies.
Target Audience
Doppl's primary customers are pharmaceutical companies, biotech firms, and research institutions involved in preclinical drug development and personalized medicine research.
Features
- Customized organoid line development for specific tissues and diseases
- Compound profiling using healthy gastro-intestinal organoid models for toxicity screening
- Epithelial fluid transport screening using gastro-intestinal organoid models
- Oncology models for insights into oncology programs
- Gastrointestinal organoid models for inflammatory disease research
- Advanced screening platform for rare disease therapeutic approaches
- Standardized tumor-immune cell co-culture workflow for immuno-oncology
- ADME-Tox profiling on various healthy organoid models
- Target validation services including in silico analysis, RNA sequencing, protein expression, and immunohistochemistry
- Organoid-immune cell co-cultures to evaluate the safety and efficacy of novel immune engager therapies